Dr. Krop is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
333 Cedar St
New Haven, CT 06520Phone+1 203-785-4095- Is this information wrong?
Summary
- Ian Krop, MD, PhD is the Chief Clinical Research Officer and Associate Cancer Center Director for Clinical Research at the Yale Cancer Center. He also serves as the Chief Scientific Officer for the Translational Breast Cancer Research Consortium (TBCRC).
Dr. Krop received his undergraduate, medical and PhD degrees from Johns Hopkins University. He subsequently completed his residency in Internal Medicine at Johns Hopkins Hospital, and fellowship in hematology and medical oncology at Dana-Farber.
Dr. Krop is a translational investigator focused on the development of novel molecularly targeted therapies and immunotherapies for breast cancer, and elucidating the mechanisms of resistance to these treatments. The majority of his effort is concentrated in the area of HER2+ breast cancer. He was a leader in the development of the antibody-drug conjugates trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan
Education & Training
- Johns Hopkins University School of MedicinePhD, 1996
- Brigham and Women's HospitalFellowship, 1999 - 2002
- Johns Hopkins University School of MedicineResidency, 1996 - 1999
- Johns Hopkins University School of MedicineClass of 1996
Certifications & Licensure
- FL State Medical License 2023 - Present
- CT State Medical License 2022 - 2024
- MA State Medical License 2002 - 2023
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.Toshio Shimizu, Noboru Yamamoto, Takahiro Kogawa, Francesca Pisetzky, Priyanka Basak, Cindy Lau, Rebecca S Heist, Jacob Sands, Aditya Bardia, Aaron Lisberg, Ian Krop, ...> ;Cancer Treatment Reviews. 2024 Apr 1
- HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.Zheqi Li, Otto Metzger Filho, Giuseppe Viale, Patrizia dell'Orto, Leila Russo, Marie-Anne Goyette, Avni Kamat, Denise A Yardley, Vandana Gupta Abramson, Carlos L Artea...> ;The Journal of Clinical Investigation. 2024 Feb 1
- TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.Filipa Lynce, Laura E Stevens, Zheqi Li, Jane E Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M Force, Tufia C Haddad, Naoto Ueno, Vered Stea...> ;Breast Cancer Research. 2024 Jan 31
- Join now to see all
Press Mentions
- Maximizing ADCs in Breast Cancer: Targets, Sequencing, and MoreJune 13th, 2023
- Will HER3 Targeting Change Breast Cancer Care?July 6th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: